Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia facing physicians with recent epidemiological studies estimating that there are over 11 million AF sufferers in the seven major economies. The prevalence of AF is predicted to increase two- to three-fold in the next 50 years. The most significant side effect of AF is stroke, and it is estimated that between 15 and 25% of strokes are caused by AF. Current therapies are problematic, and there is an undisputed requirement for a new generation of drugs that operate through novel mechanisms in this area of substantial unmet medical need.
Professor John Camm, Chairman of Xention's Clinical Advisory Board, discusses the importance of developing new pharmaceuticals to treat atrial fibrillation.
Play in Windows Media Player